// App-Quantinova.ai

460 : Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Researchers

Presenter

  • Farhad Ravandi

Principal Investigators

  • Asad Bashey

  • Wendy Stock

  • James M. Foran

  • Raya Mawad

  • Daniel Egan

  • William Blum

  • Allen Yang

  • Alessandro Pastore

  • Chelsea Johnson

  • Shuo Zheng

  • Musa Yilmaz

  • Alice S. Mims

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • BMT Grp of Georgia, Atlanta, GA

  • Department of Medicine, Section of Hematology and Oncology, The University of Chicago, Chicago, IL

  • Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL

  • Swedish Cancer Institute, Seattle, WA

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute,Seattle,Estados Unidos

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • OncoFluor, Inc., San Diego, CA

  • Translational Clinical Oncology, Novartis Institutes for Biomedical Research, East Hanover, NJ

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Blastic plasmacytoid dendritic cell neoplasm

  • B-cell acute lymphoblastic leukemia

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

Biomarkers

  • Cluster of Differentiation 2AP

  • Twist-related protein 1

Drug/Treatment

  • XmAb14045

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved